Generic Semaglutide Canada Coming Soon.
What is generic semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed by Novo Nordisk under the brand name Ozempic. It works by mimicking a natural hormone that stimulates insulin release, suppresses glucagon, and slows gastric emptying, together lowering blood glucose levels.
Generic semaglutide contains the same active ingredient, same dosage form, and same strength as the brand-name product. Health Canada's approval confirms bioequivalence, meaning the generics perform the same way in the body as Ozempic.
DRUG INFORMATION - Indications & approved uses
Generic semaglutide is approved in Canada for the same indications as Ozempic. Prescriptions must be issued by a licensed healthcare provider based on individual clinical assessment.
Primary indication: Type 2 diabetes mellitus to improve glycemic control in adults, as an adjunct to diet and exercise.
Cardiovascular indication: Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Drug class GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist)
Route of administration: Subcutaneous injection into the abdomen, thigh, or upper arm. Once weekly, any time of day.
Brand equivalent Ozempic® (semaglutide) by Novo Nordisk
Store refrigerated at 2°C to 8°C before first use. After first use, store below 30°C for up to 56 days.
SAFETY - Contraindications & precautions
Semaglutide should not be used in patients with certain conditions. Discuss your full medical history with your prescriber before starting treatment.
Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Known hypersensitivity to semaglutide or any excipients
Type 1 diabetes mellitus (not approved for this use)
Diabetic ketoacidosis treatment
Pregnancy: discuss risks with your physician
Common side effects
Most side effects are gastrointestinal and tend to improve as the body adjusts, particularly following dose escalations.
Very common (>10%) Nausea, vomiting, diarrhea, constipation, abdominal pain
Common (1–10%) Decreased appetite, dyspepsia/heartburn, belching or flatulence, fatigue, injection site reactions
DISCLAIMER
Medical disclaimer: The information on this page is intended for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Generic semaglutide is a prescription medication in Canada. It must be prescribed by a licensed healthcare provider following an appropriate clinical assessment. Always consult your physician, pharmacist, or other qualified health professional with any questions regarding a medical condition or medication. Do not disregard professional medical advice or delay seeking it because of information on this page.
Ozempic® is a registered trademark of Novo Nordisk A/S. This page is not affiliated with, endorsed by, or connected to Novo Nordisk, Apotex Inc., or Dr. Reddy's Laboratories. Product availability, pricing, and DIN numbers are subject to change. Information is provided in good faith based on publicly available Health Canada regulatory data.
